There is a consensus recognition that CDK4/6 inhibition as monotherapy for ER+ BC is restricted to early adaptative response, with the complex of cyclin D1 and CDK2 mediating residual cell‐cycle entry.6 This evidence concerns the gene CDK4 and breast cancer.